Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA polymerase II, I and III subunit L (POLR2L) is a highly conserved protein subunit shared by the three major nuclear DNA-dependent RNA polymerases (I, II, and III), which catalyze the transcription of DNA into various classes of RNA, including messenger RNA (mRNA), ribosomal RNA (rRNA), and several small non-coding RNAs. The POLR2L protein is characterized by four conserved cysteines forming an atypical zinc-binding domain. As a core component, it plays a structural and functional role in the assembly, stability, and activity of the multi-subunit RNA polymerase complexes essential for gene expression in all eukaryotic cells. Mutations in POLR2L have been associated with rare hereditary diseases such as Cockayne syndrome and Hyperparathyroidism 2 with jaw tumors[1][2][7][9]. No drugs are known to specifically target this subunit due to its fundamental and ubiquitous role in cell survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA polymerase II, I and III subunit L (POLR2L).